Steatotic liver disease risk scores compared for predicting cirrhosis
For patients with steatotic liver disease (SLD), the steatosis-associated fibrosis estimator (SAFE) score demonstrated the greatest net benefit for predicting cirrhosis, according to a study published online Sept. 21 in JAMA Internal Medicine.
A study published in JAMA Internal Medicine found that the steatosis-associated fibrosis estimator (SAFE) score was most effective in predicting cirrhosis in patients with steatotic liver disease (SLD). The research, led by Catherine Mezzacappa from the Yale School of Medicine, compared nine risk scores for predicting cirrhosis and hepatocellular carcinoma (HCC) in noncirrhotic SLD patients.
Over a 10-year period, 3.96% of the cohort developed cirrhosis and 0.35% developed HCC. The SAFE score stood out for its ability to discriminate cirrhosis risk, followed by the fibrosis-4 index (FIB-4) and aspartate aminotransferase-to-platelet ratio. For HCC prediction, the SAFE and Tate scores had the highest discrimination. Among the scores evaluated, the SAFE score provided the greatest net benefit for cirrhosis prediction, with a 10-year cirrhosis risk of 2.5% and a net benefit of 0.019 per 100 individuals classified as high risk.
The study emphasizes the importance of evaluating test performance at clinically relevant thresholds.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
